TABLE 2.
Clinical characteristics of core binding factor acute myeloid leukemia.
| Inv (16) (n = 24) | T(8;21) (n = 51) | p | |
|---|---|---|---|
| ELN risk classification | |||
| Favorable | 17 (70.8%) | 41 (80.3%) | 0.325 |
| Intermediate | 4 (16.6%) | 3 (5.8%) | |
| Adverse | 3 (12.5%) | 7 (13.7%) | |
| Sex (male) | 15 (62.5%) | 32 (62.7%) | 0.984 |
| Age | 41 (17–74) | 38 (4–77) | 0.218 |
| Activating kinase mutation | 11 (45.8%) | 18 (35.2%) | 0.382 |
| Chromatin modifier | 1 (4.1%) | 2 (3.9%) | 0.960 |
| Transcription factor | 0 | 2 (3.9%) | 0.325 |
| Cohesin | 0 | 0 | / |
| DNA methylation | 5 (20.8%) | 5 (9.8%) | 0.190 |
| Tumor suppressor | 16 (66.6%) | 22 (43.1%) | 0.057 |
| Spliceosome | 2 (8.3%) | 0 | 0.037 |
| Kitmut | 8 (33.3%) | 9 (17.6%) | 0.130 |
| Flt3mut | 5 (20.8%) | 5 (9.8%) | 0.492 |
| WT1mut | 16 (66.6%) | 21 (41.5%) | 0.039 |
| Non‐mut | 5 (21%) | 16 (31.3%) | 0.343 |
| Cytogenetic categories | |||
| Autosomal abnormalities | 3 (12.5%) | 9 (17.6%) | 0.571 |
| Sex chromosome abnormalities | 1 (4.1%) | 10 (19.6%) | 0.078 |
| Complex karyotype | 1 (4.1%) | 9 (17.6%) | 0.109 |
| Extramedullary involvement | 0 | 1 (1.9%) | 0.490 |
| CNS leukemia | 5 (20.8%) | 3 (5.8%) | 0.051 |
| WBC(×109/L) | 28.24 (4.6–391.6) | 9.8 (0.95–124.99) | 0.001 |
| HGB(g/L) | 89 (55–139) | 70.5 (35–132) | 0.002 |
| PLT(×109/L) | 36 (9–424) | 20.9 (5–184) | 0.06 |
| BM blasts (%) | 66.75 (20–96.5) | 46.5 (20–94.5) | 0.002 |
| ECOG | 1 (1–2) | 1 (−4) | 0.416 |
| Type of AML | |||
| De novo | 22 (91.6) | 50 (98%) | 0.189 |
| Secondary | 2 (8.3%) | 1 (1.9%) | |
| Induction chemotherapy | |||
| IA | 10 (41.6%) | 20 (39.2%) | 0.840 |
| Others | 14 (58.3%) | 31 (60.7%) | |
| Consolidation therapy | |||
| Chemotherapy | 11 | 16 | 0.538 |
| Auto‐HSCT | 2 | 8 | |
| Allo‐HSCT | 11 | 26 | |
| UCBT | 0 | 1 | |
Abbreviations: Allo‐HSCT, allogeneic hematopoietic stem cell transplantation; BM, bone marrow; CNS, central nervous system; HGB, hemoglobin; Mut, mutation; Others induction therapy contains DA, VA, MA, HA, HAE, HAA, CAG, DCAG, AZA‐HAG, Priming; PLT, palatelete; WBC, white blood cell.